Novavax Inc reports results for the quarter ended June 30 - Earnings Summary

• Novavax Inc NVAX reported quarterly adjusted earnings of 62 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 99 cents. The mean expectation of six analysts for the quarter was for a loss of 11 cents per share. Wall Street expected results to range from -64 cents to 34 cents per share.

• Revenue fell 42.4% to $239.24 million from a year ago; analysts expected $147.96 million.

• Novavax Inc's reported EPS for the quarter was 62 cents​.

• The company reported quarterly net income of $106.51 million.

• Novavax Inc shares had risen by 6.8% this quarter and lost 16.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 235.6% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Novavax Inc is $18.00, about 62.6% above its last closing price of $6.73

This summary was machine generated from LSEG data August 6 at 02:13 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)